Outcome of the Board meeting held today, i.e., August 07, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Pharmaids Pharmaceuticals approved unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose sharply to Rs 111.53 lakhs from Rs 16.65 lakhs in Q1 FY25, but the company reported a much wider standalone loss after tax of Rs 436.30 lakhs (vs Rs 162.34 lakhs loss a year ago), mainly due to a spike in finance costs (Rs 111 lakhs vs Rs 1.27 lakhs) and higher other expenses. On a consolidated basis, revenue grew about 41% to Rs 666.36 lakhs, but the loss widened to Rs 531.53 lakhs from Rs 312.45 lakhs. The auditor included an Emphasis of Matter noting the planned disinvestment of the company's entire 66.50% stake in Anugraha Chemicals via postal ballot (e-voting ending August 14, 2025). The Board also appointed three new senior management personnel (Dr. Sidde Gowda as VP Operations, Dr. Jagadeesh M as VP Discovery Services, and Mr. Shivananda Murthy as CIO) and accepted the resignation of CEO Dr. S. Prasad for personal reasons, effective close of business August 7, 2025.
Shareholders should note that losses are widening significantly even as revenue grows, driven by rising finance costs and operating expenses. The simultaneous exit of the CEO and a major divestment (Anugraha Chemicals) signal ongoing restructuring, which could affect short-term stock sentiment.